Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Recruiting · NCT05351593 · Registry updated 2026-07-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | primary central nervous system lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-07-14 | NCT05351593 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| James Rubenstein | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Francisco | San Francisco | United States | 294 |